Psychopharmacology

Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of Directors

Retrieved on: 
Tuesday, September 20, 2022
Psychopharmacology, Central nervous system, Lists of diseases, CFO, Wendell Pritchett, Ketamine, Amyotrophic lateral sclerosis, Psychiatry, U.S. Securities and Exchange Commission, Company, KTTA, Multiple sclerosis, Cordis, Wharton School of the University of Pennsylvania, Merchant Marine Academy, Therapy, Amyotrophy, Forward-looking statement, Patient, Johnson & Johnson, CEO, MBA, BS, Health administration, Nasdaq, Board of directors, Board, CNS, MIAMI, Research, ALS, GLOBE, SEC, University, United States Merchant Marine Academy, Pharmaceutical industry

Mr. Novak replaces Dr. Yassine Bendiabdallah, who stepped down from the Board on September 14, 2022.

Key Points: 
  • Mr. Novak replaces Dr. Yassine Bendiabdallah, who stepped down from the Board on September 14, 2022.
  • Mr. Novak brings financial acumen and extensive expertise in product development, regulatory approval, commercial activities, and a track record of delivering substantial value for stockholders.
  • Professor Lawrence Steinman, Chairman of the Board of Pasithea, stated, We are pleased to welcome Mr. Novak to our Board of Directors.
  • The Board would like to express its appreciation to Dr. Bendiabdallah for all his dedication and contributions to Pasithea.

Pasithea Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Friday, September 9, 2022
KTTA, Lists of diseases, Ketamine, MIAMI, Therapy, Psychiatry, Research, GLOBE, Conference, Psychopharmacology, Nasdaq, Biotechnology, Patient, Pharmaceutical industry

MIAMI BEACH, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (Pasithea or the Company), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that its Chief Executive Officer, Dr. Tiago Reis Marques, will deliver a virtual presentation at the H.C. Wainwright 24th Annual Global Investment Conference, being held from September 12-14, 2022 in New York, as follows:

Key Points: 
  • MIAMI BEACH, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (Pasithea or the Company), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that its Chief Executive Officer, Dr. Tiago Reis Marques, will deliver a virtual presentation at the H.C. Wainwright 24th Annual Global Investment Conference, being held from September 12-14, 2022 in New York, as follows:
    During the conference Pasithea will be participating in virtual 1x1 meetings that can be requested via H.C. Wainwright.
  • Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders.
  • With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders.
  • Pasithea is also focused on addressing the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.

35th annual Psych Congress features CEO Alliance for Mental Health's Unified Vision for Transforming Mental Health and Substance Use Care

Retrieved on: 
Wednesday, September 7, 2022
Clifford Whittingham Beers, Patient, University, Lists of diseases, Evolution, Psych, Research, Mental health, Austine School, Doctor of Psychology, Psychiatry, National Alliance, Hope, LPC, Mental disorder, Health, Psychopharmacology, LINC, Senior, EMS, Education, Organization, Faculty, Student, EMT, SAWC, VRTX, Treatment Advocacy Center, MA, Symposium, Dignity, CME, News, WETA, Congress, American Psychiatric Association, American, Practitioner, Medicine, Pharmaceutical industry, Psychotherapy, Nursing

MALVERN, Pa., Sept. 7, 2022 /PRNewswire-PRWeb/ -- Experts from industry-leading organizations in the mental health field will lead the 35th annual Psych Congress with the Unified Vision for Transforming Mental Health and Substance Use Care.

Key Points: 
  • MALVERN, Pa., Sept. 7, 2022 /PRNewswire-PRWeb/ -- Experts from industry-leading organizations in the mental health field will lead the 35th annual Psych Congress with the Unified Vision for Transforming Mental Health and Substance Use Care.
  • Organized by HMP Global, the leading healthcare events and education company, Psych Congress will be held September 17-20 in New Orleans.
  • Psych Congress is designed and accredited for all members of the mental health team, including psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, students, residents and fellows, and other mental health professionals.
  • To view the Unified Vision for Transforming Mental Health and Substance Use Care, visit nami.org .

STEMTECH CORPORATION ANNOUNCES PROFESSOR DR. BANKOLE JOHNSON JOINS THEIR LIFE SCIENCES ADVISORY BOARD

Retrieved on: 
Tuesday, September 6, 2022
COVID-19, CEO, Life, Academy, Professor, CASA, Dietary Supplement Health and Education Act of 1994, Science, CNN, Report, Anatomy, GLOBE, Medicine, Leadership, Company, Founder, Adult, HBO, Biomedical sciences, EMF, Government, Time, Lists of diseases, Master's degree, Addiction, 48th Daytime Emmy Awards, Department, CGMP, DSHEA, Psychiatry, Pharmacology, Dentistry, Forbes, Larkin University, Security (finance), NASDAQ, Psychopharmacology, Patent, MD, Alumnus, B cell, Private Securities Litigation Reform Act, Health, University, Television, Neuroscience, Policy, University of Virginia, Education, History of the University of Maryland, College Park, Bone marrow, Pharmaceutical industry, Management

MIRAMAR, FL, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Stemtech Corporation (Stemtech) (OTCQB: STEK), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, today announced that Professor Dr. Bankole Johnson joins the Stemtech Corporation Life Sciences Advisory Board (LSAB).

Key Points: 
  • MIRAMAR, FL, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Stemtech Corporation (Stemtech) (OTCQB: STEK), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, today announced that Professor Dr. Bankole Johnson joins the Stemtech Corporation Life Sciences Advisory Board (LSAB).
  • Stemtech Corporation President and Chief Operating Officer, John W. Meyer, said Professor Dr. Bankole Johnson joining Stemtechs Life Sciences Advisory Board is a great addition to our Team.
  • Charles S. Arnold, Stemtech Corporation Chairman and CEO stated that with the addition of Professor Dr. Bankole Johnson, Stemtech continues to make forward strides toward our strategic goal of providing leading-edge and advanced products for health and wellness.
  • Professor Dr. Johnson also functions as a Professor of Biomedical Sciences at Larkin University in Miami.

DoubleRainbow Biosciences and Kelai Pharmaceuticals to collaborate on novel natural compound therapeutics

Retrieved on: 
Monday, August 22, 2022
Metabolomics, Plant, Synthetic biology, Research, Mental, Therapy, Impact, PMID, Administration, Advanced Drug Delivery Reviews, Psychopharmacology, ADD, Science, Quality of life, Organization, Double, Government budget balance, Double Rainbow, Kavalactone, GLOBE, Medicine, Addiction, Intellectual property, Genomics, Health, Environment, Life, Patient, Fine chemical, Pharmaceutical industry, Medicinal plants, Disease, Piper

Lexington, MA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- DoubleRainbow Biosciences (Double Rainbow), a sustainable biotech company harnessing bioengineering to improve the quality of human health, announced today a new research collaboration with Kelai Pharmaceuticals (Kelai) to explore the potential of biosynthetic kavalactone therapeutics.

Key Points: 
  • Lexington, MA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- DoubleRainbow Biosciences (Double Rainbow), a sustainable biotech company harnessing bioengineering to improve the quality of human health, announced today a new research collaboration with Kelai Pharmaceuticals (Kelai) to explore the potential of biosynthetic kavalactone therapeutics.
  • Using Double Rainbows proprietary HARMONYTM platform, the companies will leverage synthetic biology to help Kelai unlock the potential of these natural compounds through sustainable biosynthetic production.
  • As a company, our mission includes doing no harm in the name of doing good, remarks Dr Jacqueline Jacques, Chief Executive Officer of Kelai Pharmaceutical.
  • The supply chain for a natural molecule could be exhausted with the creation of even one new drug.

Turning Point of Tampa Opens Drug and Alcohol Detoxification Program

Retrieved on: 
Friday, August 12, 2022
Death, Woman, Illegal drug trade, GLOBE, Joint, Lists of diseases, Wisconsin Department of Children and Families, Society, Substance abuse, Department, Nursing, Robin, Man, Patient, ASAM, Adult, Turning Point, American Society of Addiction Medicine, Joint Commission, Physician, DCF, Addiction, Heart, Certification, Addiction medicine, Point, Alcoholism, Drug, Residential care, Hospital, Pharmaceutical industry, Fentanyl, Psychopharmacology, MD

Tampa, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Turning Point of Tampa, a leading treatment provider in Tampa, Florida is pleased to announce the expansion of services to include medical detoxification from drugs and alcohol.

Key Points: 
  • Tampa, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Turning Point of Tampa, a leading treatment provider in Tampa, Florida is pleased to announce the expansion of services to include medical detoxification from drugs and alcohol.
  • As a family run drug and alcohol rehab program for over 35 years, Turning Point of Tampa is committed to ensuring the highest level of care for those seeking services.
  • Dr. Singh says, The Turning Point of Tampa Drug and Alcohol Detox Program offers proven and supportive evidence based withdrawal management for our patients.
  • Our drug and alcohol rehab program at our residential treatment center is designed for individuals struggling with a drug or alcohol use disorder.

Addiction Medicine Doctor Tampa, Florida – Dr. Hardeep Singh Named to Tampa Magazines’ 2022 Top Doctors List

Retrieved on: 
Friday, August 5, 2022
Woman, GLOBE, Lists of diseases, Society, Man, Patient, Rest, ASAM, Adult, American Society of Addiction Medicine, Physician, Addiction medicine, Point, Pharmaceutical industry, Publishing, Psychopharmacology

Tampa, Aug. 05, 2022 (GLOBE NEWSWIRE) -- The team at Turning Point of Tampa is proud to congratulate Dr. Hardeep Singh, Medical Director for receiving the Top Doctors 2022 honor from Tampa Magazine.

Key Points: 
  • Tampa, Aug. 05, 2022 (GLOBE NEWSWIRE) -- The team at Turning Point of Tampa is proud to congratulate Dr. Hardeep Singh, Medical Director for receiving the Top Doctors 2022 honor from Tampa Magazine.
  • He is a Fellow of the ASAM (American Society of Addiction Medicine) and a past President of the Tampa Psychiatric Society.
  • Our annual Top Doctors edition has become one of our most popular issues, says Shawna Wiggs, group publisher of Tampa Magazines.
  • The 2022 Top Doctors list will be available in the August 2022 edition of TAMPA Magazine, South Tampa Magazine, Tampa Downtown Magazine and TAMPA Digest Magazine, as well as online at tampamagazines.com.

LB Announces Publication of Phase 1 Clinical Study of LB-102

Retrieved on: 
Tuesday, July 19, 2022
Research, Technology, Other Technology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Lists of diseases, Schizophrenia, Half-life, Amisulpride, Patient, Pharmacokinetics, Plasma, Safety, BID, Trial of the century, CNS, Human, LB, Dopamine, Pharmaceutical industry, Psychopharmacology, PANSS

The article, titled "A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D2/3/5-HT7 inhibitor" (Biernat et al.

Key Points: 
  • The article, titled "A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D2/3/5-HT7 inhibitor" (Biernat et al.
  • LB-102 is being developed by LB as a potential treatment for schizophrenia and other psychiatric disorders.
  • This clinical study enrolled 64 healthy volunteers and was the first time LB-102 had been dosed in humans.
  • Based on these encouraging data, as well as data from a subsequent clinical study of dopamine receptor occupancy using positron emission tomography, LB is planning a Phase 2 clinical study of LB-102 in patients with acute exacerbated schizophrenia.

FAMILY FIRST ADOLESCENT SERVICES APPOINTS JONATHAN STEVENS, MD MPH AS MEDICAL DIRECTOR

Retrieved on: 
Tuesday, July 19, 2022
Baylor College of Medicine, Adult, CEO, ADHD, Hospital, Pharmacokinetics, Child, Depression, Menninger Foundation, Patient, Science, Program, Psychopharmacology, PALM, Harvard University, Medical director, Anxiety, Genetic testing, Bipolar, Behavioural sciences, Baylor University, Adolescence, Associate, Multimedia, OCD, Industry, Medicine, Family, Behavioral Problems, Foundation (nonprofit), Obesity, Psychiatry, BEACH, Lists of diseases, American Academy of Child and Adolescent Psychiatry, Psychosis, Mental health, Medical device, Pharmaceutical industry

PALM BEACH GARDENS, Fla., July 19, 2022 /PRNewswire/ -- Family First Adolescent Services (FFAS), a leading provider of adolescent residential treatment for substance use disorder and mental health, is proud to announce the appointment of Dr. Jonathan Stevens as its Medical Director. Dr. Stevens' expertise will add enhanced psychiatric services to a program renowned for its work in providing trauma-informed adolescent care.

Key Points: 
  • PALM BEACH GARDENS, Fla., July 19, 2022 /PRNewswire/ -- Family First Adolescent Services (FFAS), a leading provider of adolescent residential treatment for substance use disorder and mental health, is proud to announce the appointment of Dr. Jonathan Stevens as its Medical Director.
  • Dr. Stevens' expertise will add enhanced psychiatric services to a program renowned for its work in providing trauma-informed adolescent care.
  • Dr. Stevens' expertise adds enhanced psychiatric services to the renowned trauma-informed adolescent treatment program.
  • For more information on Family First Adolescent Services, visit www.familyfirstas.com
    View original content to download multimedia: https://www.prnewswire.com/news-releases/family-first-adolescent-service...

Pasithea Therapeutics Awarded a Drug Development Research Grant

Retrieved on: 
Thursday, July 14, 2022
Ketamine, Disease, Psychopharmacology, MIAMI, SEC, Antibody, Biotechnology, LLC, Acquisition, MND, Therapy, Psychiatry, Company, Survival, Neurodegeneration, Lists of diseases, Integrin, Patient, CEO, Amyotrophic lateral sclerosis, Brain, GLOBE, Human, Diagnosis, Motor neuron, Death, Spinal cord, Nasdaq, Heredity, Motor neuron disease, Sporadic group, Forward-looking statement, HIV disease progression rates, FDA, Research, ALS, Drug development, Life expectancy, KTTA, Neutralizing antibody, The Beast, SOD1, Pharmaceutical industry

MIAMI BEACH, Fla., July 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the availability of an AUD $1 million (U.S. $694,000) drug development research award following the Company's acquisition of Alpha-5 integrin, LLC (“Alpha-5”). The grant was awarded by FightMND, the largest independent funder of amyotrophic lateral sclerosis (“ALS”)/motor neuron disease (“MND”) research in Australia.

Key Points: 
  • -- AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction --
    MIAMI BEACH, Fla., July 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) Pasithea Therapeutics Corp. (Nasdaq: KTTA) (Pasithea or the Company), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the availability of an AUD $1 million (U.S. $694,000) drug development research award following the Company's acquisition of Alpha-5 integrin, LLC (Alpha-5).
  • The grant was awarded by FightMND, the largest independent funder of amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) research in Australia.
  • Ultimately, we aim to help ALS/MND patients who are in dire need of effective therapy, stated Dr. Tiago Reis Marques, CEO of Pasithea.
  • Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders.